<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631903</url>
  </required_header>
  <id_info>
    <org_study_id>ZPV-200 EXT</org_study_id>
    <nct_id>NCT01631903</nct_id>
  </id_info>
  <brief_title>Extension of Study ZPV-200</brief_title>
  <official_title>A Phase 2, Multi-Center, Five-Arm, Parallel Design, Randomized, Single-Blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Confirmed by Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, pharmacokinetics and efficacy of four
      doses of vaginally administered Proellex in premenopausal women with uterine fibroids
      confirmed by ultrasound.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Scores</measure>
    <time_frame>3 or 4 months depending on treatment arm</time_frame>
    <description>The primary efficacy endpoint will be bleeding assessed using the change in PBAC scores from the 4 weeks prior to Visit 2 to the 4 weeks prior to Visit 10</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Arm 2 (3mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (6 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (12 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 (24 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PK arm (12 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK arm requires one additional 24 hour PK assessment at V3 and daily visits between visits 2 and 3 for drug trough sample collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telepristone acetate 12 mg</intervention_name>
    <description>12 mg, vaginal capsule, once daily for 4 months</description>
    <arm_group_label>PK arm (12 mg)</arm_group_label>
    <other_name>Proellex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telepristone acetate 3 mg</intervention_name>
    <description>3 mg, vaginal capsule, once daily for 3 months</description>
    <arm_group_label>Arm 2 (3mg)</arm_group_label>
    <other_name>Proellex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telepristone acetate 6 mg</intervention_name>
    <description>6 mg, vaginal capsule, once daily for 3 months</description>
    <arm_group_label>Arm 3 (6 mg)</arm_group_label>
    <other_name>Proellex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telepristone acetate 12 mg</intervention_name>
    <description>12 mg, vaginal capsule, once daily, for 3 months</description>
    <arm_group_label>Arm 4 (12 mg)</arm_group_label>
    <other_name>Proellex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telepristone acetate 24 mg</intervention_name>
    <description>24 mg, vaginal capsule, once daily for 4 months</description>
    <arm_group_label>Arm 5 (24 mg)</arm_group_label>
    <other_name>Proellex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult females between 18 and 47 years of age with uterine fibroids confirmed
             by ultrasound. Normal, or abnormal but non-clinically significant, transvaginal
             ultrasound. History of menstrual events occurring in regular cycles.

          -  Agreement not to attempt to become pregnant.

          -  Agreement to limit alcohol consumption to no more than 2 drinks per week and to avoid
             alcohol consumption within 48 hours before each visit.

          -  Ability to complete a daily subject diary and study procedures in compliance with the
             protocol.

          -  Agrees to use the condoms provided and no other method of birth control (hormonal
             methods, contraceptive sponge, spermicide or cervical cap) over the course of the
             study.

          -  Has a negative pregnancy test at the Screening and Baseline visits. An exception for
             the pregnancy test requirement will be granted for subjects providing verification of
             surgical sterilization.

          -  A Body Mass Index (BMI) between 18 and 39 inclusive.

          -  Is available for all treatment and follow-up visits.

          -  Subject is able to insert vaginal suppositories.

          -  Subject is willing to exclusively use sanitary napkins (no tampons) during study
             duration.

        Exclusion Criteria:

          -  Subject is a post-menopausal woman, defined as either; six (6) months or more
             (immediately prior to screening visit) without a menstrual period, or prior
             hysterectomy and/or oophorectomy.

          -  Subject is pregnant or lactating or is attempting or expecting to become pregnant
             during the 7 month study period.

          -  Women with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 1.5x
             ULN AND total bilirubin exceeding 1.5xULN at screening and confirmed on repeat).

          -  Received an investigational drug in the 30 days prior to the screening for this study.

          -  Women with a history of PCOS.

          -  Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids,
             DHEA or hormonal products for at least 2 weeks prior to screening and during the
             study.

          -  Use of oral contraceptives in the preceding 30 days. Use of Depo-Provera® in the
             preceding 6 months.

          -  Has an IUD in place.

          -  Women currently using narcotics.

          -  Women currently taking cimetidine or spironolactone.

          -  Clinically significant abnormal findings on screening examination or any condition,
             which in the opinion of the investigator, would interfere with the participant's
             ability to comply with the study instructions or endanger the participant if she took
             part in the study.

          -  Participation in study ZP-204.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>47 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.reprosrx.com</url>
    <description>Sponsor's corporate web page</description>
  </link>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <last_update_submitted>April 15, 2014</last_update_submitted>
  <last_update_submitted_qc>April 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

